Lawsuit Information Center
Gabapentin lawsuits are now being filed over dementia, mild cognitive impairment, memory loss, and other serious cognitive problems. New research has raised concerns about a link between these injuries and long-term or repeated gabapentin use.
These cases are still developing, and we are in the early rounds of this. The deeper our lawyers dig into these cases, the more we believe in them.
Now, the litigation is starting to move forward. It seems the center of the litigation will be in state court in Philadelphia. A mass tort program for lawsuits involving gabapentin, sold as Neurontin, and pregabalin, sold as Lyrica, has been established there.
No one is saying the drug does not work for many patients. The core allegation is that drug companies failed to give doctors and patients adequate warnings about the potential cognitive risks of gabapentin, especially when the drug was prescribed for off-label uses where the benefits were often uncertain.
Our law firm is accepting potential gabapentin dementia lawsuits. We are reviewing claims involving long-term or repeated gabapentin use followed by dementia, mild cognitive impairment, early-onset dementia, or significant documented memory loss. If you or a loved one took gabapentin or Neurontin and later developed dementia, mild cognitive impairment, or severe memory loss, the next step is to call a lawyer. You can reach us at 800-553-8082 or get a free online consultation.
Do not stop taking gabapentin without speaking to your doctor. Suddenly stopping gabapentin can cause withdrawal symptoms and may increase seizure risk in some patients.
Gabapentin Lawsuit Quick Status
Current claims: Filed lawsuits allege that gabapentin and pregabalin caused dementia and other neurocognitive injuries and that manufacturers failed to give adequate warnings.
Main allegations: Failure to warn, negligent design, misrepresentation, and other product liability claims. The lawsuits involve both the failure to warn and the over-the-top marketing of these drugs.
Current litigation stage: Philadelphia established a state court gabapentinoid mass tort program on September 8, 2026. It included 28 cases as of October 13, involving gabapentin and pregabalin. This is separate from a federal MDL although we might see that develop as well.
Prior gabapentin litigation: Pfizer and related companies have paid hundreds of millions of dollars in Neurontin litigation stemming from off-label marketing and antitrust claims. We are now turning to the injuries these drugs can cause.
Cases our lawyers are reviewing: We are currently accepting claims involving long-term or repeated gabapentin or Neurontin use followed by dementia, mild cognitive impairment, early-onset dementia, or serious documented cognitive decline.
Gabapentin Lawsuit Updates
October 20, 2026: Philadelphia Establishes Gabapentin and Lyrica Mass Tort Program
Gabapentin dementia lawsuits now have a coordinated state court program in Philadelphia. The program was established last month with a case management order filed on October 8.
As of October 13, 28 cases are in the program. That count covers cases involving gabapentin and pregabalin.
The lawsuits name Pfizer, Greenstone, Pharmacia & Upjohn, Pharmacia, and Viatris. They allege that the companies failed to warn about dementia and other neurocognitive injuries while promoting Neurontin and Lyrica for widespread use.
In almost all of these drug side effect cases, a key point in this litigation will be what Pfizer, etc. knew about an early-onset dementia risk as far back as the early 1990s. So the question is what did the companies know before the more recent studies became public, and what did they tell prescribing doctors?
September 2026: Our Firm Is Again Accepting Gabapentin Dementia Cases
Our law firm is again accepting potential gabapentin dementia and cognitive impairment cases. We are reviewing claims involving long-term or repeated gabapentin or Neurontin use followed by dementia, mild cognitive impairment, early-onset dementia, or serious documented memory loss.
Our lawyers are reviewing medical records, prescription history, diagnosis, state law, and brand-name versus generic use to determine which claims may be viable. If you contact us, that is the work we will be doing to evaluate your claim.
See More Gabapentin Lawsuit Updates
June 2026: Gabapentin Dementia Claims Are Being Investigated
Law firms are now reviewing potential gabapentin dementia and cognitive impairment claims, although most firms that handle mass torts have yet to jump in. The focus is on patients who took gabapentin repeatedly, especially for off-label pain conditions, and later developed dementia, cognitive impairment, or serious memory loss. Our focus is really on the diagnosed dementia cases but we are looking at other cognitive injuries.
These Neurontin claims are in the investigation stage. That means lawyers are collecting records, reviewing medical literature, analyzing state law, and determining which cases may be strong enough to file.
2025: New Chronic Back Pain Study Raises Concern
The 2025 chronic low back pain study has become one of the strongest pieces of evidence for potential claims. It reported increased dementia and mild cognitive impairment diagnoses among patients with repeated gabapentin prescriptions, with higher risks in non-elderly adults and in patients with more prescriptions.
This study does not prove causation by itself. But it gives plaintiffs a concrete scientific basis for asking whether doctors and patients should have been warned more clearly about Neurontin’s cognitive risks.
2024: Study Shows Mixed Evidence in Older Adults With Cognitive Impairment
A 2024 study in older adults with existing cognitive impairment did not find a significant association between gabapentin initiation and cognitive or functional decline over one to two years, but it did report increased falls. This study will likely be used by the defense to argue that the science is mixed.
Plaintiffs will need strong experts who can explain why some studies are more relevant to certain patients than others, especially younger patients, chronic pain patients, and patients with repeated prescriptions.
2023: Taiwan Database Study Reports Higher Dementia Risk
The 2023 Taiwan database study found an increased dementia risk among patients exposed to gabapentin or pregabalin and reported higher risks with increasing cumulative exposure. Plaintiffs will likely rely on this study as part of the broader body of evidence.
Defendants will argue that gabapentin and pregabalin were grouped together and that foreign insurance database findings do not prove causation in individual U.S. cases. Both sides will have arguments. That is why expert testimony will drive these cases.
2019: FDA Adds Breathing Risk Warning
The FDA required new gabapentinoid warnings for serious breathing problems in 2019, especially in patients using opioids or other central nervous system depressants, patients with respiratory disease, and older adults. This warning is not about dementia, but it shows that gabapentin safety concerns have continued to evolve long after the drug became widely used.
Who May Qualify for a Gabapentin Dementia Lawsuit?
Every case is different, but the strongest potential Neurontin lawsuit will usually involve a patient who took gabapentin repeatedly or long term and later developed a serious cognitive diagnosis. A casual user who took a short course of gabapentin and later had vague memory complaints will be much harder to pursue.
Our law firm is focused on cases that contain most of these elements:
- You took gabapentin or Neurontin for months or years.
- You received multiple prescriptions, including six or more prescriptions. That was a research threshold in the 2025 study, not a legal eligibility rule.
- You were prescribed gabapentin for an off-label condition such as chronic back pain, migraines, anxiety, fibromyalgia, or general chronic pain.
- You were later diagnosed with dementia, mild cognitive impairment, early-onset dementia, or significant documented cognitive decline.
- You were under age 65 when the cognitive diagnosis was made.
- You did not have major pre-existing dementia risk factors that clearly explain the diagnosis.
- Your medical records show a timeline connecting gabapentin use and later cognitive decline.
- You or your family noticed confusion, memory problems, functional decline, or personality changes after repeated gabapentin use.
The under-65 issue is not a requirement of ours, but it is a big issue. Why? Early-onset dementia claims will be easier to separate for victims below 65 because it takes some of the juice out of the defense argument that it is normal age-related cognitive decline. That does not mean older patients have no case. We think many older adults will still have viable claims. But there is no question the defendants will argue that dementia in older patients is common and often caused by other medical factors.
So our attorneys have to review these cases from the angle of what changed, and when. When you ask us to review your claim, you do not need to reconstruct every doctor visit before calling. We just want to know your story to see if it tracks with what we think can be a successful case. Tell us when the medication started, when you first noticed problems, and what diagnosis followed. We can work from there. The point is to build the history from records and what your family actually observed, rather than assume that two events occurring in the same person prove one caused the other.
Is Memory Loss the Same as Dementia?
Not really. If you felt sleepy or foggy while taking gabapentin, that is different from being diagnosed with dementia or mild cognitive impairment. When you contact us, tell us what you or your family noticed and what your doctors have said about it. If there has not been a diagnosis, medical evaluation comes first. We cannot diagnose the cause of memory problems from an intake form.
Brand-name or generic? Please tell us whether you took Neurontin, generic gabapentin, or both. If you do not know, your pharmacy records may answer that question. This can affect whether there is a defendant we can pursue, even where the injury and medication history otherwise look strong.
Cases Our Lawyers Are Unlikely to Pursue
Our lawyers do not believe that every gabapentin user with memory problems has a viable lawsuit. Cases we think are weaker or no case at all involve advanced age, short-term drug use, unclear diagnosis, no medical documentation, or a long list of alternative causes that make connecting the dots between the drug and the cognitive issues difficult.
Certainly, cases involving a patient who had a prior dementia diagnosis before taking gabapentin will be challenging.
Cases may also be more difficult when the only product used was generic gabapentin. Generic drug lawsuits face complicated federal preemption defenses because generic manufacturers are generally required to match the brand-name label. There is legal theory, called innovator liability, that can get us around this generic problem. We are too early in the game to know whether that theory can be applied here.
Gabapentin Lawsuit Settlement Amounts and Payouts
If you are trying to figure out what your gabapentin dementia case might be worth, we cannot give you a useful dollar range yet. We would like to and our firm is usually aggressive in telling victims what we think about what we expect settlement amounts to be. When we feel like we have a clearer handle on where this litigation is going, we will update this section with our estimate of what payouts might be.
One thing is for sure is that these cases have the potential to be big. Cognitive injuries command big settlement and verdicts if you can prove the defendant is responsible. In these Neurontin cases, damages will include medical expenses, future dementia care, assisted living costs, in-home care, lost wages, loss of earning capacity, pain and suffering, emotional distress, loss of independence, and the impact on family members. The sum of these numbers can get into the millions very quickly. In wrongful death cases, damages may include funeral expenses, loss of companionship, and other damages allowed by state law.
If we get past who is responsible for the injury, the biggest value driver will be the severity of the cognitive injury. A mild memory complaint with limited treatment is not the same as early-onset dementia that forces a person out of work and into assisted care.
What Is Gabapentin?
Gabapentin is one of the most commonly prescribed medications in the United States. It is sold under the brand name Neurontin and is also available as a generic. Doctors prescribe Neurontin for seizures, shingles-related nerve pain, and a long list of off-label conditions, including back pain, neuropathy, anxiety, migraines, fibromyalgia, sleep problems, and other chronic pain complaints.
Gabapentin is an anticonvulsant medication. Neurontin was originally developed by Parke-Davis, later tied to Warner-Lambert and Pfizer.
The FDA-approved uses for Neurontin are narrower than many patients realize. The current label identifies two main uses: (1) management of postherpetic neuralgia in adults, which is nerve pain after shingles, and (2) adjunctive therapy for partial-onset seizures in adults and pediatric patients with epilepsy. In regular medical practice, however, gabapentin is prescribed for many conditions outside those approved uses.
Off-label prescribing in and of itself is not awful. Doctors prescribe FDA-approved drugs for conditions not listed on the label when they believe the medication may help. But drug companies generally cannot market a drug for unapproved uses, and they must provide adequate warnings about known or reasonably knowable risks.
Gabapentin became popular in part because it was seen as a safer alternative to opioids. It was not originally viewed as highly addictive. It was cheap after generic versions became available. Doctors under pressure to reduce opioid prescribing increasingly turned to gabapentin for chronic pain patients. That shift helped make gabapentin a routine medication in pain clinics, primary care offices, and even postoperative care.
The problem is that popularity can outrun proof, and that seems to be what happened here. That is the concern now driving gabapentin dementia lawsuits.
Why Are Patients Filing Gabapentin Lawsuits?
Gabapentin lawsuits are being filed because several studies have reported associations between gabapentin use and later cognitive problems. These studies do not prove every patient who took gabapentin and later developed dementia has a lawsuit. They do not prove gabapentin caused every case of memory loss. But they do raise enough concern that lawyers, doctors, and patients are paying attention.
The strongest cases will not be built on a vague complaint that a patient “felt foggy” after taking gabapentin. Cognitive fog, dizziness, and sedation have long been known issues with the drug. The emerging lawsuits are focused on something more serious: diagnosed dementia, mild cognitive impairment, early-onset dementia, or major cognitive decline after repeated or long-term gabapentin use.
The logic is simple. Gabapentin affects the central nervous system. It has long been associated with sedation, dizziness, gait instability, and confusion. It was heavily used for off-label conditions. Now research suggests a relationship between repeated gabapentin prescriptions and later dementia or cognitive impairment. If manufacturers knew or should have known about those Neurontin risks, the label should have clearly warned doctors and patients.
The defense argument is also predictable. Drug companies will say, because it is true, that dementia has many causes. They will argue that observational studies cannot prove causation. They will also argue that many patients took generic gabapentin, for which they are not responsible.
That is the fight in a nutshell. Plaintiffs will argue that the accumulating research justified stronger warnings and that manufacturers left doctors and patients without information they needed to weigh the risks. Defendants will argue that the science is not strong enough and that the injuries are caused by other factors.
What the Philadelphia Complaints Allege
The Philadelphia complaints focus on a warning, but they go beyond that. They allege negligence, negligent design, negligent and fraudulent misrepresentation, and breach of express and implied warranties, along with negligent and strict liability failure-to-warn claims.
The complaints also allege that manufacturers concealed negative information about Neurontin, overstated its benefits for unapproved uses, and then encouraged doctors and patients to move to Lyrica. For someone who took both drugs, that makes the full prescription history important. We want to know which medication you took first, whether you switched, and when the cognitive problems began.
The 2025 Gabapentin Dementia Study That Triggered This
The study getting the most attention was published in Regional Anesthesia & Pain Medicine in 2025. Researchers examined adults with chronic low back pain using the TriNetX database, which includes de-identified electronic health records from many healthcare organizations. The study compared patients who received gabapentin prescriptions with similar patients who did not.
The results were alarming. After matching patients to control for demographics, comorbidities, and other pain medications, researchers found that patients with six or more gabapentin prescriptions had a higher incidence of dementia and mild cognitive impairment within ten years. The reported risk ratio was 1.29 for dementia and 1.85 for mild cognitive impairment. Among non-elderly adults ages 18 to 64, the reported risk was higher, with more than double the risk of dementia and mild cognitive impairment compared to patients not prescribed gabapentin.
The study also found higher rates of dementia and mild cognitive impairment among patients with 12 or more prescriptions than among patients with three to eleven prescriptions. That measures prescription frequency, not the dose each patient actually took.
This study gave plaintiffs’ lawyers a stronger scientific foundation than they had before. It also focuses on chronic low back pain, one of the most common off-label reasons patients receive gabapentin. That is relevant because many potential claimants were not taking gabapentin for seizures or shingles-related nerve pain. They were taking it for chronic pain complaints, where the risk-benefit calculation looks very different.
Other Studies on Gabapentin and Cognitive Decline
The 2025 study is the big study but it is not the only one lawyers are looking at to support these claims. A 2023 study in Frontiers in Pharmacology examined gabapentin or pregabalin exposure using Taiwan’s National Health Insurance Research Database. That study included more than 200,000 patients and reported a higher risk of dementia among patients exposed to gabapentin or pregabalin compared with matched non-exposed patients. The risk increased with higher cumulative defined daily doses.
That study is useful for plaintiffs because it suggests a dose-response relationship. In drug litigation, dose-response evidence is useful to victims’ lawyers. If higher exposure is associated with higher risk, plaintiffs’ attorneys can argue that the relationship is less likely to be random.
Another study, published in Frontiers in Pharmacology in 2022, looked at older adults with normal cognition using data from the National Alzheimer’s Coordinating Center. Researchers found that gabapentin initiation was associated with certain neurocognitive and functional declines, including changes in Clinical Dementia Rating scores and functional measures. The study also found increased falls in a subgroup.
What the 2026 Research Adds
A 2026 review in Drugs & Aging combined five observational studies involving 325,245 participants. It found 28% higher estimated odds of Alzheimer’s disease and related dementias among gabapentinoid users. That category includes gabapentin and pregabalin.
There is an important catch. The studies varied considerably, and the association was no longer statistically significant when the analysis was limited to studies judged to have a low risk of bias. The authors rated the overall certainty of the evidence as low and said the findings could not establish causation.
For your case, that means we need more than a prescription and a diagnosis. We need experts who can explain which findings apply to your medication history and why. That work is part of deciding which claims we can bring.
Why Off-Label Use Matters
Off-label use will be a major issue in these lawsuits. Gabapentin was approved for seizures and postherpetic neuralgia. But many patients received it for chronic back pain, general neuropathy, anxiety, insomnia, migraines, fibromyalgia, and other conditions.
There is no question that a patient taking gabapentin for epilepsy may face a very different risk-benefit calculation than a patient taking it for routine low back pain. Seizures can be life-threatening. Postherpetic neuralgia can be severe. But chronic back pain is often treated with multiple therapies, and if gabapentin provides limited benefit for some patients while carrying potential cognitive risks, the warning and prescribing decision becomes more important.
Pfizer’s history with off-label Neurontin marketing will also get attention. In 2004, Warner-Lambert agreed to pay $430 million to resolve criminal and civil allegations tied to illegal promotion of Neurontin for unapproved uses. Federal prosecutors described a national off-label marketing campaign that included promotion for conditions not approved by the FDA. That resolution included a $240 million criminal fine and $190 million in civil settlements. The separate $190 million antitrust settlement discussed below came in 2014.
That old settlement did not compensate dementia victims. It did not resolve today’s potential cognitive impairment claims. But it shows that Neurontin’s off-label marketing history is not speculation. So we will argue that the same off-label expansion that made gabapentin so widely used also exposed patients to risks they were not adequately warned about.
What Does the Gabapentin Label Warn About?
The Neurontin prescribing information warns about several serious risks, including drug reaction with eosinophilia and systemic symptoms, anaphylaxis and angioedema, effects on driving and operating heavy machinery, somnolence, dizziness, suicidal behavior and ideation, withdrawal-related seizure risk, respiratory depression, pediatric neuropsychiatric adverse reactions, and other concerns.
That is a lot of bad stuff. But the label does not contain a clear warning that gabapentin may increase the risk of dementia or mild cognitive impairment. Plaintiffs will argue that a central nervous system drug used repeatedly over months or years should have carried stronger cognitive warnings as evidence developed.
Prior Neurontin Settlements and Verdicts
Gabapentin already has a significant litigation history, but prior Neurontin settlements were mostly about off-label marketing, insurance payments, and antitrust issues. They were not dementia settlements for injured patients.
| Amount | Type of case | What it means |
|---|---|---|
| $430 million | 2004 federal criminal and civil resolution over off-label Neurontin promotion | Important history, but not a dementia victim compensation fund. |
| $142 million | Kaiser verdict tied to off-label marketing and payment for prescriptions | Shows juries and courts have previously held Pfizer accountable for Neurontin marketing conduct. |
| $325 million | 2014 Neurontin marketing and sales practices settlement with third-party payers | Resolved payer claims related to off-label promotion, not individual dementia claims. |
| $190 million | 2014 Neurontin antitrust settlement with direct purchasers | Resolved claims about delaying generic competition, not personal injury claims. |
So these are not dementia settlements. But they are still relevant to the litigation. Why? Because Neurontin’s history is pushing the envelope on off-label marketing, putting profits over patients.
Is There a Gabapentin Class Action Lawsuit?
If you are looking to join a gabapentin class action for dementia, the Philadelphia program is a mass tort involving individual lawsuits. Your claim does not become part of that program just because you took the medication. You still need a case that can be filed and supported with evidence.
That makes sense, at least on some level. Dementia injuries are highly individual. One person may have mild cognitive impairment and continue working. Another may develop early-onset dementia and need full-time care. One patient may have taken gabapentin for back pain for years. Another may have taken it briefly after shingles.
The Philadelphia program coordinates state court cases. A federal MDL is another way courts can coordinate lawsuits, but it is a different procedure. In either setting, each plaintiff keeps an individual case and damages claim. The October 1, 2026 federal MDL report does not list a gabapentin dementia MDL. That does not change the fact that the Philadelphia state court litigation is underway.
The older Neurontin class actions discussed above dealt with different claims. They do not give someone diagnosed with dementia today a way to collect compensation.
Gabapentin Lawsuit FAQs
Is there a gabapentin lawsuit?
Yes. Lawsuits alleging dementia and other neurocognitive injuries are now being coordinated in a Philadelphia state court mass tort program involving gabapentin and pregabalin. Our lawyers are accepting potential gabapentin cases for review. If you or a family member developed a serious cognitive injury after taking gabapentin, we want to look at the medication history and medical records.
Does gabapentin cause dementia?
We believe so, and new research is reporting this connection between gabapentin use and dementia or mild cognitive impairment in certain patient groups. Now that this issue has reached a critical mass and triggered lawsuits, you can expect more studies to come out to address the question of whether gabapentin causes or contributes to cognitive decline.
What injuries are lawyers reviewing?
Lawyers are primarily reviewing dementia, early-onset dementia, mild cognitive impairment, major memory loss, and serious cognitive decline after repeated or long-term gabapentin use. Ordinary dizziness or temporary brain fog may not be enough for a lawsuit. Our preference is victims under 65.
Who are the likely defendants?
You can expect to see Pfizer, Greenstone, Pharmacia & Upjohn, Pharmacia, and Viatris sued in these cases. We need to identify who made the medication you actually took, when you took it, and what law applies to your claim. Your pharmacy records will tell us a lot and we can get them for you.
Is there a gabapentin class action?
There is no class action lawsuit, but cases around the country are being filed in the Philadelphia mass tort program. Cases in the program will be coordinated together for pretrial discovery. But everyone keeps their own individual claim and damages. There have been older Neurontin class action lawsuits, but those involved marketing, payment for prescriptions, and generic competition, not the individual cognitive decline claims our lawyers are focusing on in 2026.
What is the average gabapentin lawsuit payout?
There is no average payout because the dementia litigation is still new. Our lawyers are generally quick to project settlement amounts even at early stages of a litigation but we cannot for this one. It is just really early, and there is too much we do not know. Certainly, any future settlement value would depend on the diagnosis, age, duration of use, medical expenses, lost income, care needs, and strength of causation proof. But the injury is very serious, and these could be very large settlements if all goes as planned.
Can I sue if I took generic gabapentin?
Possibly, but generic drug cases are legally difficult. Federal law gives generic manufacturers strong defenses in failure-to-warn cases. Some states may allow claims against the brand manufacturer even if the patient took a generic, but that depends on state law and case facts.
Should I stop taking gabapentin?
Do not stop taking gabapentin without talking to your doctor. This is a big deal. Stopping suddenly can be dangerous. If you are worried about memory loss, confusion, sedation, falls, or other side effects, speak with your doctor about whether tapering or switching medications is appropriate.
Is there a gabapentin lawsuit payout date?
There is no payment date for these dementia cases. The Philadelphia court program puts lawsuits into a coordinated process, but it does not set a date for settlement checks. If you are seeing a date attached to an old Neurontin settlement, it does not tell you when a dementia claim might be paid. Do not wait for a settlement announcement to ask about your case. Filing deadlines can run while litigation is developing.
Is there a gabapentin settlement claim form?
Our free consultation form is where you can ask us to review a potential dementia claim. Tell us who took gabapentin, how long they took it, and what diagnosis followed. This is a request for legal help, not a claim against one of the old Neurontin settlement funds. If we believe we can help, we will explain the next steps.
Getting Help from a Lawyer with Your Compensation Claim
If you or a loved one took gabapentin and later developed dementia, cognitive impairment, or severe memory loss, our lawyers are ready to listen and discuss with you whether we think you may have a viable claim. You can reach us at 800-553-8082 or get a free online consultation.